BORN Expands With Alkeon B2B Market Network Platform Transforming Commercial Models, Starting With the Trade Show Industry
2.3.2021 17:12:00 EET | Business Wire | Press release
BORN, announces the expansion of innovative B2B subsidiary Alkeon, the world's first global SaaS market-network combining content, community, and commerce to connect buyers and sellers through a best-in-class platform, powered by machine learning. The 2020 pandemic generated a tremendous and immediate need for companies of all categories to pivot at a moment’s notice, with over 10,000 global trade shows completely upended due to cancellations of physical events. BORN, a purpose driven lifestyle company dedicated to reimagining the discovery, transaction and connection of the B2B and B2C communities, found an opportune moment to quickly scale and enhance their technology solutions. The company formally established Alkeon, an enterprise dedicated to supporting the needs of companies who are adapting to the current and future landscapes and need the right partner to support them through the process.
Combining aesthetic and function to create designed technology, Alkeon is a market-network company that enables brands to create an always-on commercial model, digitally optimize their existing infrastructure, capture detailed audience insights and more. Starting with the immediate needs of the global trade show market, Alkeon represents over 15,000 buyers and 150,000 new products by the end of the year. The B2B solution has seen hyper growth and solidified contracts from some of the most influential global trade shows including Tranoï (part of GL Events), Cosmoprof, Brand Assembly, Reassemble, Esxence and Bridal Harrogate.
Founder and CEO of BORN, Jean-Christophe states, “We have seen gaps in the B2B and B2C supply chains for several years, with many aspects of both still operating with analogue systems that lack the benefits of full digital capabilities, audience intelligence and ways to expand and enhance traditional commercial models. The last year has made these gaps stark, leaving many companies in a position to innovate quickly in order to survive. The trade show audience was not only deeply disrupted, but is crucial for global commerce. The tech solutions that we’ve developed have implications for several industries, but we chose to focus on this important category that supports economies around the world. Longterm, businesses, including trade shows, will need a hybrid model that combines the best of technology with the great benefits of physical interaction. We’re creating the solutions for now and well into the future.”
Alkeon’s technology platform empowers trade shows to digitally transform their business, and expand their business internationally with buyers, agents, showrooms and distributors. Brands using BORN's Alkeon service can select a package that ranges from $99 a month to $15,000 a year with various offerings, including intelligent matchmaking, a suite of connection tools such as in-app messaging and video meetings, actionable insights about their business such as buyer engagement and trending product reports. Alkeon offers buyers best-in-class product discovery experience powered by machine learning, delivering personalized product recommendations, curated product lists, and the ability to save products.
“Early on, we asked ourselves the question, “Why can’t B2B be beautiful?”. So we set out with the goal to delight wholesale buyers with a refined, feature-rich product discovery and purchase experience typically reserved for direct-consumer experiences.” - Brendan Wypich, Chief Design & Product Officer.
The platform provides a sleek interface for each brand to present their story and products so that buyers can make quick and informed business decisions. Alkeon streamlines a brand’s workflows by providing full transparency and clear tracking of buyer order flows from initial interest through to purchase order all while staying in constant contact with the buyer. The result is a simplified wholesale buying process that future-proofs the brand’s operations while scaling their business footprint.
BORN began developing the Alkeon technology well before the pandemic hit. Alkeon offers a pleasing and educational discovery experience along with a seamless infrastructure. With quick expansion, BORN and Alkeon will chart the course for the future of retail and wholesale, using the best of the latest technology to learn and adapt, curate and personalize and allow for broader market access. The benefits of the technology have game-changing implications for tradeshows, showrooms, brands, media companies, press agents and buyers.
About BORN:
BORN specializes in digital, data-led solutions to digitize retail supply chains and reimagine discovery and transaction online. BORN owns Alkeon, a suite of B2B solutions and software products that digitize tradeshows and showrooms, as well as Born.com, a platform connecting thousands of luxury design-led brands with premium retailers. BORN is led by CEO Jean-Christophe Chopin, ex-founder of E*Trade EU and Verisign EU.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005254/en/
Contact information
Press: Stephanie Gotch SG@PartnersAndAssoicatesAgency.com 917-583-8606
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
